![Norbert Bender](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Norbert Bender
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di Norbert Bender
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Public Company | Food: Specialty/Candy | 8 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Norbert Bender tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Evolva SA
![]() Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Officer/Principal Founder Director/Board Member | |
SYMETIS SA | Biotechnology | Director/Board Member Director/Board Member | |
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director of Finance/CFO | |
Burrill LLC
![]() Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
Ferring International Center SA
![]() Ferring International Center SA Pharmaceuticals: MajorHealth Technology Ferring International Center SA develops, manufactures and markets products in the fields of urology, gynaecology and obstetrics. It also specializes in the fields of gastroenterology and endocrinology. The company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. | Pharmaceuticals: Major | President | |
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
York University | College/University | Masters Business Admin | |
McGill University | College/University | Undergraduate Degree | |
Ferring Pharmaceuticals A/S
![]() Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | President | |
Phytera, Inc.
![]() Phytera, Inc. Miscellaneous Commercial ServicesCommercial Services Phytera, Inc. develops plant-based and marine-based pharmaceuticals. The company is headquartered in Shrewsbury, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
University of Coimbra | College/University | Undergraduate Degree | |
The University of Liverpool
![]() The University of Liverpool Other Consumer ServicesConsumer Services The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom. | College/University | Doctorate Degree | |
Banque Lombard Odier & Cie SA (Investment Management)
![]() Banque Lombard Odier & Cie SA (Investment Management) Investment ManagersFinance Banque Lombard Odier & Cie SA (Investment Management) (Lombard Odier-IM) is the investment management division of Banque Lombard Odier & Cie, a subsidiary of Compagnie Lombard Odier SCmA in Switzerland. The firm was founded in 2002 when Lombard Odier & Cie and Darier Hentsch & Cie. merged. They are headquartered in Geneva with branches and representative offices throughout Switzerland, Europe, the Americas, Asia Pacific and the Middle East. Lombard Odier-IM provides private banking and asset management services to institutions, family-owned businesses and high-net worth individuals. They also provide a range of support services for independent intermediaries. | Investment Managers | Corporate Officer/Principal | |
Fondation Fournier Majoie pour l'Innovation EtUtPub
![]() Fondation Fournier Majoie pour l'Innovation EtUtPub Miscellaneous Commercial ServicesCommercial Services Fondation Fournier Majoie pour l'Innovation EtUtPub is a social services provider based in Brussels, Belgium. The Belgian company provides social services. | Miscellaneous Commercial Services | Director/Board Member | |
S*BIO Pte Ltd.
![]() S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Pharmaceuticals: Major | Director/Board Member | |
OMEROS CORPORATION | Pharmaceuticals: Major | Director/Board Member | |
MerLion Pharmaceuticals Pte Ltd.
![]() MerLion Pharmaceuticals Pte Ltd. Miscellaneous Commercial ServicesCommercial Services MerLion Pharmaceuticals Pte Ltd. provides drug discovery and development services. It focuses on developing its lead antibacterial candidate, finafloxacin, through early and mid-stage clinical trials. The company was founded in 2002 and is headquartered in Singapore. | Miscellaneous Commercial Services | Chairman | |
University of Cambridge | College/University | Director/Board Member | |
University of Geneva | College/University | Masters Business Admin | |
Nura, Inc.
![]() Nura, Inc. Pharmaceuticals: MajorHealth Technology Nura, Inc. discovers and develops pharmaceutical products. It offers products for the treatment of neurodegenerative diseases such as Parkinson's & Alzheimer's diseases and behavioural disorders such as depression, anxiety, schizophrenia, obesity, and addiction. The company was founded in August 2003 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member | |
Aravis AG
![]() Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Investment Managers | Founder | |
iSD Immunotech ApS
![]() iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Biotechnology | Chief Executive Officer | |
Hovione Farmaciência SA
![]() Hovione Farmaciência SA Pharmaceuticals: MajorHealth Technology Hovione FarmaCiencia SA manufactures and distributes active pharmaceutical ingredients. Its services include contract manufacturing services, off-patent API products, proprietary product licensing, and supporting capabilities. The company was founded by Diane de Lancastre Houssemayne Du Boulay Villax, Ivan Villax, Nicholas de Horthy and Andrew Onody in 1959 and is headquartered in Loures, Portugal. | Pharmaceuticals: Major | Director/Board Member | |
Acesion Pharma ApS
![]() Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman | |
CAMLIN FINE SCIENCES LIMITED | Chemicals: Specialty | Director/Board Member | |
DePuy Synthes, Inc.
![]() DePuy Synthes, Inc. Medical SpecialtiesHealth Technology The DePuy Synthes Inc. provides orthopaedic and neuro products and services in the areas of joint reconstruction, trauma, spine, sports medicine, neuro, cranio-maxillofacial, power tools and biomaterials. The company was founded in 1895 and is headquartered in Warsaw, IN. | Medical Specialties | Corporate Officer/Principal | |
University of Basel | College/University | Director/Board Member | |
Acino Pharma AG
![]() Acino Pharma AG Pharmaceuticals: MajorHealth Technology Acino Pharma AG engages in the development, production, and distribution of chemical and pharmaceutical products. It also acquires, manages, and sells participating interests in firms, real estate, and intellectual property rights. The company was founded in 1961 and is headquartered in Liesberg, Switzerland. | Pharmaceuticals: Major | Director of Finance/CFO | |
Synthes, Inc.
![]() Synthes, Inc. Medical SpecialtiesHealth Technology Synthes, Inc. engages in the development, production, and marketing of instruments, implants, as well as biomaterials for surgical fixation, correction, and regeneration of the human skeleton and its soft tissues. The company was founded in 1999 and is headquartered in Solothurn, Switzerland. | Medical Specialties | Corporate Officer/Principal | |
Centro Universitário da FEI | College/University | Director/Board Member | |
ACINO HOLDING AG | Pharmaceuticals: Major | Director of Finance/CFO | |
STRAUMANN HOLDING AG | Medical Specialties | Director of Finance/CFO | |
Cell Medica Switzerland AG
![]() Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director of Finance/CFO | |
PricewaterhouseCoopers, Inc.
![]() PricewaterhouseCoopers, Inc. Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., PricewaterhouseCoopers, Inc. is a South African company that provides accounting, auditing, and bookkeeping services. The company is based in Sunninghill, South Africa. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
SANTHERA PHARMACEUTICALS HOLDING AG | Pharmaceuticals: Major | Chairman | |
Enduro Genetics ApS
![]() Enduro Genetics ApS Miscellaneous Commercial ServicesCommercial Services Enduro Genetics ApS is a Danish biotechnology research company that specializes in developing bio products. The company is based in Copenhagen, Denmark. Enduro Genetics was founded by Peter Rugbjerg and Christian Munck. The CEO is Christian Munch. | Miscellaneous Commercial Services | Director/Board Member | |
Evolva AG | Director/Board Member | ||
Protera SAS
![]() Protera SAS Food: Major DiversifiedConsumer Non-Durables Protera SAS manufactures protein-based ingredients to address critical challenges in food, agriculture, the environment, and human health. Its products include Guard, Sense, antioxidant proteins, and foaming and emulsifying proteins. The company was founded by Leonardo Álvarez and Francia Navarrete and is headquartered in Neuilly-sur-Seine, France. | Food: Major Diversified | Chairman | |
Novozymes BioloAg A/S
![]() Novozymes BioloAg A/S BiotechnologyHealth Technology Novozymes BioloAg A/S provides research and development for biotechnology products and processes. It participates in The BioAg Alliance to commercialize BioAg assets and competencies within microbial research, development, and production. The company was founded on October 22, 2007 and is headquartered in Bagsvaerd, Denmark. | Biotechnology | Chief Executive Officer | |
Ferring Holding, Inc.
![]() Ferring Holding, Inc. Pharmaceuticals: MajorHealth Technology Part of Ferring Holding SA, Ferring Holding, Inc. is a company that manufactures and sells pharmaceuticals. The company is based in Parsippany, NJ. | Pharmaceuticals: Major | Chairman |
Statistiche
Distribuzione geografica
Svizzera | 22 |
Danimarca | 9 |
Stati Uniti | 8 |
Canada | 3 |
Portogallo | 3 |
Settori
Health Technology | 26 |
Commercial Services | 10 |
Consumer Services | 9 |
Finance | 6 |
Process Industries | 2 |
Posizioni
Director/Board Member | 75 |
Corporate Officer/Principal | 28 |
Chairman | 14 |
President | 9 |
Founder | 8 |
Contatti più connessi
- Borsa valori
- Insiders
- Norbert Bender
- Connessioni Società